|
|
|
| Diagnostic Value of Serum CEA, CA125, CA153 Combined with HER2 in Breast Cancer |
| FU Jingfen |
| The Third Hospital of Nanchang, Nanchang 330009, China |
|
|
|
|
Abstract Objective: To explore the diagnostic value of serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) combined with human epidermal growth factor receptor 2 (HER2) level in breast cancer. Method: A total of 108 cases of breast cancer and 110 cases of breast benign tumor were selected from June 2019 to June 2021 in the Third Hospital of Nanchang and respectively set as the breast cancer group and the breast benign tumor group. In addition, 100 cases who underwent health examination in the same period were selected as the healthy control group. The serum levels of CEA, CA125, CA153 and HER2 in the three groups were detected, and the diagnostic value of the combination of four serum indicators for breast cancer was evaluated by using receiver operating characteristic curve. Result: The serum CEA, CA125, CA153, HER2 levels in the breast cancer group and the breast benign tumor group were higher than those in the healthy control group, and the serum indexes levels above the breast cancer group were higher than those in the breast benign tumor group (P<0.05). The levels of the above serum indexes in patients with breast cancer stage Ⅲ, Ⅳ were higher than those in stage Ⅰ, Ⅱ (P<0.05). The sensitivity and area under curve of combined diagnosis of serum CEA, CA125, CA153 and HER2 were higher than those of single diagnosis of breast cancer (P<0.05), and there were no significant differences in specificity compared with those of single diagnosis of each index (P>0.05). Conclusion: Serum CEA, CA125, CA153 and HER2 levels are all abnormally elevated in breast cancer, which are related to clinical stages, all of them have certain diagnostic value for breast cancer, but combined detection can improve the diagnostic value.
|
|
Received: 19 September 2022
|
|
|
|
|
|
|
